Market Place
Sourcing Support
Vu Technologies and Moffitt Use NVIDIA DGX for 3D Tumor Imaging
20 May 2026 //
PR NEWSWIRE
First Rytelo lowers LR-MDS Study Debuts at EHA 2026
12 May 2026 //
GLOBENEWSWIRE
Moffitt Cancer Center Selects Dicom for Digital Pathology
30 Apr 2026 //
PR NEWSWIRE
Dyve Biosciences, Moffitt Cancer Center Unveil Positive Study
14 Apr 2026 //
PHARMIWEB
Moffitt Cancer Center Partners with Cryoport
14 Jan 2025 //
CONTRACTPHARMA
First Patient Enrolled in STK11 Lung Cancer Phase I at Moffitt
24 Sep 2024 //
GLOBENEWSWIRE
Moffitt and Fulgent Pharma partner on personalised cancer therapies
15 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Moffitt, Fulgent Pharma Partner To Revolutionize Cancer Therapeutics
14 May 2024 //
BUSINESSWIRE
Anixa starts subject treatment in Phase I ovarian cancer cell therapy trial
16 Aug 2022 //
CLINICALTRIALSARENA
Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance
30 Aug 2021 //
PRNEWSWIRE
Moffitt Researchers Identify New Relevant Target for PARP Inhibitor Talazoparib
29 Jul 2021 //
NEWSWISE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.